Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27439667 | 0.93 | ADORA2A (0.45) | ADORA2AADORA2BEIF4A3MAPK1DYRK1A | |
| SCHEMBL13394497 | 0.83 | PDPK1 (0.40) | EIF4A3MAPK1DYRK1A | |
| SCHEMBL5681952 | 0.81 | ADORA2A (0.53) | ADORA2AADORA2BMAPK1DYRK1ACYP1A2 | |
| SCHEMBL8415606 | 0.78 | ADORA2A (0.50) | ADORA2AADORA2BMAPK1DYRK1ACYP1A2 | |
| SCHEMBL25843809 | 0.76 | EIF4A3 (0.39) | EIF4A3 | |
| SCHEMBL13122059 | 0.76 | ADORA2A (0.52) | ADORA2AADORA2BMAPK1CYP1A2CHEK1 | |
| SCHEMBL23867190 | 0.76 | LRRK2 (0.48) | — | |
| SCHEMBL562141 | 0.75 | ADORA2A (0.47) | ADORA2AADORA2BMAPK1DYRK1ACYP1A2 | |
| SCHEMBL8273052 | 0.75 | ADORA2A (0.47) | ADORA2AADORA2BDYRK1ACYP1A2CHEK1 | |
| SCHEMBL24747202 | 0.75 | ADORA2A (0.47) | ADORA2AADORA2BMAPK1DYRK1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 4/4885EIF4A3 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.